Research Studies: A MULTI-CENTER DOUBLE BLIND RANDOMIZED 12 MONTH PLACEBO-CONTROLLED STUDY TO EVALUATE THE LIPIDLOWERING EFFECT SAFETY AND TOLERABILITY OF AVE5530 25 MG/DAY AND 50MG/DAY WHEN ADDED TO ONGOING STABLE STATIN THERAPY (HMG-COA REDUCTASE INHIBITOR (Sanofi Study)

« Research Studies

A MULTI-CENTER DOUBLE BLIND RANDOMIZED 12 MONTH PLACEBO-CONTROLLED STUDY TO EVALUATE THE LIPIDLOWERING EFFECT SAFETY AND TOLERABILITY OF AVE5530 25 MG/DAY AND 50MG/DAY WHEN ADDED TO ONGOING STABLE STATIN THERAPY (HMG-COA REDUCTASE INHIBITOR (Sanofi Study)

PI: Stephen Glasser, MD